Retatrutide

Description

Retatrutide Reference Material | Triple Incretin Receptor Agonist

Retatrutide is a synthetic acylated peptide sequence designed as a simultaneous agonist at the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR). As a triple incretin receptor research ligand with published Phase 2 clinical pharmacological characterization, it provides researchers with well-defined receptor binding affinities and pharmacokinetic parameters for experimental design.

Receptor Pharmacology

• GLP-1R: Class B GPCR on beta cells, hypothalamic neurons, and enteroendocrine cells — mediates glucose-stimulated insulin secretion (GSIS) and beta-cell cAMP dynamics
• GIPR: Expressed on beta cells, adipocytes, and osteoblasts — amplifies incretin cAMP signaling through receptor co-activation mechanisms under active investigation
• GCGR: Hepatocyte-expressed GPCR — mediates hepatic glycogenolysis, gluconeogenesis, and fatty acid oxidation signaling

Laboratory Research Applications

• Triple receptor binding affinity and selectivity assays
• Incretin receptor co-activation and cAMP signaling studies
• Beta-cell secretory function and GSIS research
• Hepatic lipid oxidation and GCGR pathway studies
• Comparative single/dual/triple agonist pharmacology studies
• GIPR/GLP-1R receptor interaction and heterodimerization research

Specifications

• Form: Lyophilized powder
• Purity: ≥98% (HPLC verified)
• Storage: 2–8°C; -20°C long-term

For laboratory research use only. Not for human or veterinary use.